Feedback Form
Join, Follow & Connect
Join Modern Healthcare's LinkedIn group Follow Modern Healthcare on Twitter Join Modern Healthcare's Facebook group Join Modern Healthcare's Flickr group Get a Modern Healthcare news feed
 
 
Comment Buy Reprints Print Article Share on LinkedIn Share on Facebook Share on Twitter Email this page to a colleague
Healthcare Business News
 

Four H1N1 vaccines are approved by FDA


By Jessica Zigmond
Posted: September 16, 2009 - 11:45 am ET
Tags:

The Food and Drug Administration said it has approved four vaccines against the 2009 H1N1 influenza virus, popularly known as swine flu, which caused the World Health Organization to declare a global flu pandemic this summer. Expected within the next four weeks, the vaccines were manufactured by CSL, MedImmune, Novartis Vaccines and Diagnostics, and Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group. According to the FDA, all four companies made the vaccines using the same processes, which the agency said have a long record of producing safe seasonal flu vaccines.

“The H1N1 vaccines approved today undergo the same rigorous FDA manufacturing oversight, product quality testing and lot release procedures that apply to seasonal influenza vaccines,” Jesse Goodman, FDA's acting chief scientist, said in a news release.

People with severe or life-threatening allergies to chicken eggs, or to any other substance in the vaccine, should not be vaccinated, the FDA said. Potential side effects of the H1N1 vaccines are expected to be similar to those of seasonal flu vaccines, with the most common side effect for the injected vaccine being soreness in the area where the vaccine was injected. For the nasal spray vaccine, common side effects are runny nose, nasal congestion or sore throat, and fever in children 2 to 6 years old.

Advertisement | View Media Kit

 

Last week, Goodman joined HHS Secretary Kathleen Sebelius and experts from the National Institutes of Health and Centers for Disease Control and Prevention to announce preliminary results of the clinical trials for the vaccines, which showed the 2009 H1N1 vaccines induced a robust immune response in most healthy adults eight to 10 days after a single dose. Clinical studies about the optimal dosage for children are ongoing and “findings are expected in the near future,” the FDA said.

What do you think? Post a comment on this article and share your opinion with other readers. Submit your comments to Modern Healthcare Online at mheditorial@modernhealthcare.com. Please be sure to include your hometown and state, along with your organization and title.

Search ModernHealthcare.com:



Daily Dose MH Alert MH AM HITS Modern Physician Most Requested Advance Notice

LinkedIn Amazon Kindle Twitter Facebook Flickr News Feeds